Diagnostic and therapeutic impact of whole body positron emission tomography using fluorine-18-fluoro-2-deoxy-D-glucose in children with chronic granulomatous disease.
OBJECTIVE
To compare whole body positron emission tomography (PET) using fluorine-18-fluoro-2-deoxy-D-glucose (FDG) with computed tomography (CT) in detecting active infective foci in children with chronic granulomatous disease.


METHODS
We performed 22 whole body FDG PET studies in seven children with X linked (n = 6) or autosomal recessive (n = 1) CGD. All had clinical signs of infection and/or were evaluated prior to bone marrow transplantation (BMT). Nineteen PET studies were also correlated with chest and/or abdominal CT. All PET scans were interpreted blinded to the CT findings. Diagnoses were confirmed histologically and bacteriologically.


RESULTS
We detected 116 lesions in 22 FGD PETs and 126 lesions on 19 CTs. Only two of the latter could be classified reliably as active lesions by virtue of contrast enhancement suggesting abscess formation. PET excluded 59 lesions suspicious for active infection on CT and revealed 49 infective lesions not seen on CT. All seven active infective lesions were identified by PET, allowing targeted biopsy and identification of the infective agent followed by specific antimicrobial treatment, surgery, or subsequent BMT.


CONCLUSIONS
Identification of infective organisms is more precise if active lesions are biopsied. CT does not discriminate between active and inactive lesions. Whole body FDG PET can be used to screen for active infective lesions in CGD patients.
Güngör
T
T
Divisions of Immunology/ Haematology/Oncology/ BMT and Infectious Diseases, University Children's Hospital, Zürich, Switzerland. Tayfun.Guengoer@kispi.unizh.ch
Engel-Bicik
I
I
Eich
G
G
Willi
U V
UV
Nadal
D
D
Hossle
J P
JP
Seger
R A
RA
Steinert
H C
HC
D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001706:Biopsy; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D019788:Fluorodeoxyglucose F18 / Q000627:therapeutic use; D006105:Granulomatous Disease, Chronic / Q000000981:diagnostic imaging* / Q000628:therapy; D006801:Humans; D008297:Male; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D014055:Tomography, Emission-Computed; D014057:Tomography, X-Ray Computed; D014916:Whole-Body Irradiation
D000900:Anti-Bacterial Agents; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18